RVTY

MKT CAP:$10B

Revvity, Inc.

Market Cap

$10B

Healthcare·Medical - Diagnostics & Research·🇺🇸 United States·NYSE

Healthcare·Medical·🇺🇸·NYSE

Stock Price

$94.27-$3.88 (-3.95%)

Apr 21, 2026

Company Details

Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytic...

CEO

Prahlad R. Singh

IPO Date

Jul 6, 1965

Website

www.revvity.com

Key Metrics TTM

Revenue

$2.9B

-21.3% YoY

Net Income

$295M

EPS (Diluted)

$2.52

Free Cash Flow

$548M

Revenue / Share

$25.80

Gross Margin

50.2%

Operating Margin

14.3%

Net Margin

10.1%

FCF Margin

18.8%

P/S

3.3x

P/E

32.9x

Earnings Reports

Q1 2026

Apr 27, 2026

PENDING

FY 2025

Feb 24, 2026

$2.9BEPS $2.08

Q4 2025

Feb 24, 2026

$772M+5.9%EPS $0.87

Q3 2025

Nov 4, 2025

$699MEPS $0.40

Q2 2025

Aug 5, 2025

$720MEPS $0.47

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q2 19	$723M	$322M	$99M
Q3 19	$707M	$316M	$96M
Q4 19	$805M	$371M	$145M
Q1 20	$652M	$277M	$76M
Q2 20	$812M	$417M	$174M
Q3 20	$964M	$495M	$250M
Q4 20	$1.4B	$802M	$522M
Q1 21	$1.3B	$751M	$478M
Q2 21	$1.2B	$648M	$348M
Q4 21	$1.0B	$546M	$307M
Q3 22	$712M	$351M	$120M
Q4 22	$741M	$346M	$151M
Q4 24	$729M	$360M	$132M
Q2 25	$720M	$393M	$91M
Q3 25	$699M	$375M	$82M
Q4 25	$772M	$338M	$112M

Valuation

Quarter	P/S	P/E
Q2 19	3.4x	40.5x
Q3 19	3.4x	41.5x
Q4 19	3.4x	42.7x
Q1 20	3.4x	43.1x
Q2 20	3.3x	33.1x
Q3 20	3.0x	23.6x
Q4 20	2.6x	13.4x
Q1 21	2.2x	9.1x
Q2 21	2.0x	8.2x
Q4 21	2.0x	8.1x
Q3 22	2.3x	11.0x
Q4 22	2.6x	15.1x
Q4 24	3.0x	19.8x
Q2 25	3.4x	27.2x
Q3 25	3.4x	29.1x
Q4 25	3.3x	32.9x

Operating Cash Flow

Quarter	Operating CF	Free CF
Q2 19	$47M	$30M
Q3 19	$107M	$90M
Q4 19	$215M	$192M
Q1 20	$60M	$40M
Q2 20	$139M	$122M
Q3 20	$211M	$191M
Q4 20	$482M	$462M
Q1 21	$474M	$459M
Q2 21	$288M	$267M
Q4 21	$336M	$303M
Q3 22	$160M	$147M
Q4 22	$139M	$113M
Q4 24	$174M	$150M
Q2 25	$134M	$115M
Q3 25	$139M	$120M
Q4 25	$183M	$163M

Capital Expenditures

Quarter	CapEx
Q2 19	$17M
Q3 19	$17M
Q4 19	$23M
Q1 20	$20M
Q2 20	$17M
Q3 20	$20M
Q4 20	$20M
Q1 21	$14M
Q2 21	$20M
Q4 21	$32M
Q3 22	$13M
Q4 22	$26M
Q4 24	$24M
Q2 25	$19M
Q3 25	$19M
Q4 25	$20M

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q2 19	+12.2%	+5.5%
Q3 19	+0.5%	+1.2%
Q4 19	+6.5%	+5.2%
Q1 20	+0.6%	-0.7%
Q2 20	+12.3%	+2.3%
Q3 20	+36.4%	+16.9%
Q4 20	+68.2%	+26.0%
Q1 21	+100.4%	+43.8%
Q2 21	+51.3%	+38.0%
Q4 21	+6.6%	+1.0%
Q3 22	-47.5%	-28.9%
Q4 22	-43.3%	-28.8%
Q4 24	-40.6%	-32.2%
Q2 25	-29.9%	-12.7%
Q3 25	-1.8%	+4.3%
Q4 25	+4.2%	+11.8%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q2 19	$7M	0.9%
Q3 19	$12M	1.7%
Q4 19	$6M	0.8%
Q1 20	$3M	0.5%
Q2 20	$10M	1.2%
Q3 20	$7M	0.7%
Q4 20	$9M	0.7%
Q1 21	$5M	0.4%
Q2 21	$7M	0.6%
Q4 21	$14M	1.3%
Q3 22	$10M	1.4%
Q4 22	$12M	—
Q4 24	$5M	—
Q2 25	$10M	1.4%
Q3 25	$9M	1.3%
Q4 25	-$4M	-0.5%

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q2 19	$48M	—	$175M
Q3 19	$45M	—	$175M
Q4 19	$48M	—	$179M
Q1 20	$49M	—	$152M
Q2 20	$50M	—	$193M
Q3 20	$50M	—	$195M
Q4 20	$57M	—	$223M
Q1 21	$60M	—	$213M
Q2 21	$66M	—	$234M
Q4 21	$61M	—	$179M
Q3 22	$54M	—	$177M
Q4 22	$55M	—	$141M
Q4 24	$49M	—	$178M
Q2 25	$53M	$250M	—
Q3 25	$51M	—	$242M
Q4 25	$58M	—	$168M

Revenue Segments

Quarter	Diagnostics	Life Sciences
Q2 25	$354M	$366M
Q3 25	$356M	$343M
Q4 25	$390M	$382M

Revenue by Geography

Quarter	Americas	Asia	Europe
Q2 25	$324M	$193M	$204M
Q3 25	$307M	$189M	$202M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$670M	$0	$670M
Q2 22	$361M	$0	$361M
Q3 22	$401M	$0	$401M
Q4 22	$454M	$0	$454M
Q1 23	$2.3B	$194M	$2.5B
Q2 23	$1.3B	$739M	$2.1B
Q3 23	$1.1B	$293M	$1.4B
Q4 23	$913M	$690M	$1.6B
Q1 24	$998M	$697M	$1.7B
Q2 24	$1.2B	$706M	$2.0B
Q3 24	$1.2B	$0	$1.2B
Q4 24	$1.2B	$0	$1.2B
Q1 25	$1.1B	$0	$1.1B
Q2 25	$992M	$0	$992M
Q3 25	$931M	$0	$931M
Q4 25	$920M	$0	$920M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q2 19	112M	+0.2%	+0.2%
Q3 19	112M	+0.0%	+0.1%
Q4 19	112M	+0.1%	+0.0%
Q1 20	112M	+0.0%	+0.3%
Q2 20	112M	+0.2%	+0.3%
Q3 20	112M	+0.4%	+0.7%
Q4 20	113M	+0.2%	+0.8%
Q1 21	112M	-0.0%	+0.8%
Q2 21	112M	-0.1%	+0.5%
Q4 21	127M	+12.7%	+12.8%
Q3 22	127M	-0.1%	+12.4%
Q4 22	126M	-0.1%	+12.4%
Q4 24	122M	-3.9%	+8.2%
Q2 25	118M	-3.3%	-7.2%
Q3 25	118M	+0.2%	-7.0%
Q4 25	113M	-3.8%	-10.5%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q2 19	—	—
Q3 19	—	—
Q4 19	—	—
Q1 20	—	—
Q2 20	—	—
Q3 20	—	—
Q4 20	—	—
Q1 21	—	—
Q2 21	—	—
Q4 21	—	—
Q3 22	—	—
Q4 22	—	—
Q4 24	$66.3K	11K
Q2 25	$65.5K	11K
Q3 25	$63.5K	11K
Q4 25	$70.2K	11K

Revenue / Employee